Goisnard Antoine, Dubois Clémence, Daumar Pierre, Aubel Corinne, Depresle Marie, Gauthier Jean, Vidalinc Bernard, Penault-Llorca Frédérique, Mounetou Emmanuelle, Bamdad Mahchid
Imagerie Moléculaire et Stratégies Théranostiques, Institut Universitaire de Technologie, Université Clermont Auvergne, UMR INSERM-UCA, U1240, 63000 Clermont Ferrand, France.
BIOMARQUEURS Company, 5 Avenue Blaise Pascal, 63178 Aubière, France.
Cancers (Basel). 2021 Apr 18;13(8):1945. doi: 10.3390/cancers13081945.
Cancer spheroids are very effective preclinical models to improve anticancer drug screening. In order to optimize and extend the use of spheroid models, these works were focused on the development of a new storage concept to maintain these models in the longer term using the Triple-Negative Breast Cancer MDA-MB-231 spheroid models. The results highlight that the combination of a temperature of 4 °C and oxygen-free conditions allowed the spheroid characteristics of OptiPASS serum-free culture medium to preserve the spheroid characteristics during 3-, 5- or 7-day-long storage. Indeed, after storage they were returned to normal culture conditions, with recovered spheroids presenting similar growth rates (recovery = 96.2%), viability (Live/Dead profiles) and metabolic activities (recovery = 90.4%) compared to nonstored control spheroids. Likewise, both recovered spheroids (after storage) and nonstored controls presented the same response profiles as two conventional drugs, i.e., epirubicin and cisplatin, and two anti-PARP1 targeted drugs-i.e., olaparib and veliparib. This new original storage concept seems to induce a temporary stop in spheroid growth while maintaining their principal characteristics for further use. In this way, this innovative and simple storage concept may instigate future biological sample preservation strategies.
癌症球体是用于改进抗癌药物筛选的非常有效的临床前模型。为了优化和扩展球体模型的使用,这些研究聚焦于开发一种新的保存概念,以便使用三阴性乳腺癌MDA-MB-231球体模型长期维持这些模型。结果表明,4℃温度和无氧条件的组合能够使OptiPASS无血清培养基的球体特性在长达3天、5天或7天的保存期间得以保留。事实上,保存后将它们放回正常培养条件下,与未保存的对照球体相比,恢复后的球体呈现出相似的生长速率(恢复率=96.2%)、活力(活/死细胞成像)和代谢活性(恢复率=90.4%)。同样,恢复后的球体(保存后)和未保存的对照对两种传统药物(即表柔比星和顺铂)以及两种抗PARP1靶向药物(即奥拉帕利和维利帕利)呈现出相同的反应模式。这种新的原始保存概念似乎会使球体生长暂时停止,同时保持其主要特性以供进一步使用。通过这种方式,这种创新且简单的保存概念可能会推动未来生物样本保存策略的发展。